



**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No. : 10/677,960 Confirmation No. : 9255  
Applicant : CORINNA MAUL, et al.  
Filed : October 3, 2003  
TC/A.U. : 1614  
Examiner : Not assigned  
Docket No. : 029310.52789US  
Customer No. : 23911  
Title : USE OF SUBSTITUTED IMIDAZO[1,2-A]-PYRIDINE-3-AMIDE AND IMADAZO[1,2-A]-PYRIDINE-3-YL-AMINE  
3-AMIDE AND IMADAZO[1,2-A]-PYRIDINE-3-YL-AMINE COMPOUNDS IN PHARMACEUTICAL FORMULATIONS

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §§ 1.97 and 1.98**

**Mail Stop Missing Parts**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

**STATEMENT OF RELEVANCE**

The relevance of document BA to the subject matter of the present invention is given in the Background of the Invention in the specification of the present invention.

**CONCISE EXPLANATION OF NON-ENGLISH LANGUAGE  
DOCUMENTS**

English abstracts summarizing the disclosures of the Japanese publications and document AE are submitted herewith.


Additionally, in compliance with the concise explanation requirement under 37 CFR §1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of two corresponding foreign Search Reports citing such documents, together with an English-language version (if not already included) of that portion of the Search Report indicating the degree of relevance found by the foreign office.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.


The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

February 27, 2004

  
\_\_\_\_\_  
J. D. Evans  
Registration No. 26,269

CROWELL & MORING, LLP  
Intellectual Property Group  
P.O. Box 14300  
Washington, DC 20044-4300  
Telephone No.: (202) 624-2500  
Facsimile No.: (202) 628-8844

FORM PTO-1449    U.S. Department of Commerce Patent & Trademark Office  <b>INFORMATION DISCLOSURE STATEMENT</b> <i>(Use several sheets if necessary)</i>  Sheet 1 of 1	Attorney Docket No. 029310.52789US	Serial No. 10/677,960	
Applicant:      Corinna MAUL, et al.		Filing Date: October 3, 2003	Group:

U.S. PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)	
	AA	6,013,654	1/11/2000	TenBrink			
	AB	5,614,531	8/22/1996	Juraszyk, et al.			
	AC	5,912,256	6/15/1999	Koch, et al.			
	AD	4,450,164	5/22/1984	Bristol, et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initial	Document Number	Date	Country	Class	Sub-Class	TRANSLATION	
						Yes	No
	AE	WO 01/27109	4/19/2001	WIPO			Abstract
	AF	DE 10050663	4/18/2002	Germany			No
	AG	WO 02/02557	1/10/2002	WIPO			
	AH	WO 96/25414	8/22/1996	WIPO			
	AI	WO 96/34866	11/7/1996	WIPO			
	AJ	DE 19948437	6/7/2001	Germany			No
	AK	DE 19948438	6/7/2001	Germany			No
	AL	DE 19948434	6/7/2001	Germany			No
	AM	DE 2812914	10/12/1978	Germany			No
	AN	EP 0052016	9/5/1984	Europe			
	AO	DE 2655681	6/16/1977	Germany			No
	AP	FR 2638161	10/24/1988	France			No
	AQ	EP 0471236	3/15/1995	Europe			
	AR	JP 09176165	7/8/1997	Japan			Abstract
	AS	JP 55043059	3/26/1980	Japan			Abstract
	AT	JP 61056180	3/20/1986	Japan			Abstract
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
	AU	Kaminski, et al., "Antiulcer Agents. 2. Gastric Antisecretory, Cytoprotective, and Metabolic Properties of Substituted Imidazo[1,2-a]pyridines and Analogues", <i>J. Med. Chem.</i> , Vol. 30 (1987), pp. 2031-2046					
	AV	Teulade, et al., "Cyclisation Reactions of some 3-Nitrosoimidazol[1,2-a]-pyridines and-pyrimidines. Ring-opening/Ring-closure Reactions with Triethyl Phosphite: Reassignment by X-Ray Crystal Structure and Nuclear Magnetic Resonance", <i>J. Chem. Soc., Perkin Trans. I</i> (1983), pp. 2663-2667					
	AW	Fischer, et al., "Imidazo[1,2-a]pyridine Anthelmintic and Antifungal Agents", <i>Journal of Medicinal Chemistry</i> , Vol. 15, No. 9 (1972), pp. 982-985					
	AY	Klopman, et al., "Computer-automated structure evaluation of gastric antinuclear compounds: study of cytoprotective and antisecretory imidazo[1,2-a]pyridines and -pyrazines", <i>Mol. Pharmacol.</i> , Vol. 37, No. 6 (1990), pp. 958-965					
	AZ	Almirante, et al., "Imidazole derivatives. VI. Synthesis and pharmacological activity of nitrogen-containing derivatives of imidazo[1,2-a]pyridine", <i>Boll. Chim. Farm.</i> , Vol. 110, No. 6 (1971), pp. 322-329					
	BA	Murad, "Die Entdeckung einiger biologischer Wirkungen von Stickstoffmonoxid und seiner Rolle für die Zellkommunikation (Nobel-Vortrag)", <i>Angew. Chem.</i> , Vol. 111 (1999), pp. 1976-1989					
EXAMINER				DATE CONSIDERED			
EXAMINER:    Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.							